Brief: Inventiva Announces Changes To The Clinical Development Of Lanifibranor
04/01/2023 21:18
Jan 4 (Reuters) - Inventiva SA IVAA.PA :
* INVENTIVA ANNOUNCES CHANGES TO THE CLINICAL DEVELOPMENT OF
LANIFIBRANOR, INCLUDING PLANS FOR A NEW PHASE III TRIAL IN
PATIENTS WITH NASH AND COMPENSATED CIRRHOSIS
* INVENTIVA SA - CONFIRMATORY TRIAL OF LANIFIBRANOR CLINICAL
BENEFITS, NOW PLANNED TO BE EVALUATED IN A NEW PHASE III TRIAL
IN PATIENTS WITH NASH
* INVENTIVA SA - ONGOING PART 1 OF NATIV3 TRIAL CONTINUES AS
PLANNED
Source text for Eikon: ID:nGNX9MRlPS
Further company coverage: IVAA.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inventiva SA
See all newsFrance's Inventiva H1 net loss narrows
Brief: Euronext Includes Genfit, Inventiva In SBF120 Index; Interparfums, Verallia Excluded
Brief: Inventiva Announces Last Patient Visit In Nativ3 Phase 3 Clinical Trial Of Lanifibranor In Mash
Brief: Inventiva Announces Comprehensive Capital Structure Optimization Including Debt And Equity Financing In Advance Of The Anticipated Phase 3 Readout
Brief: Inventiva Secures Up To €150 Mln Debt Financing, Extends Debt Maturity To 2030